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This review article addresses the biological factors that influence: (i) the acquisition
of alcohol intake; (ii) the maintenance of chronic alcohol intake; and (iii) alcohol
relapse-like drinking behavior in animals bred for their high-ethanol intake. Data from
several rat strains/lines strongly suggest that catalase-mediated brain oxidation of
ethanol into acetaldehyde is an absolute requirement (up 80%–95%) for rats to
display ethanol’s reinforcing effects and to initiate chronic ethanol intake. Acetaldehyde
binds non-enzymatically to dopamine forming salsolinol, a compound that is self-
administered. In UChB rats, salsolinol: (a) generates marked sensitization to the
motivational effects of ethanol; and (b) strongly promotes binge-like drinking. The
specificity of salsolinol actions is shown by the finding that only the R-salsolinol
enantiomer but not S-salsolinol accounted for the latter effects. Inhibition of brain
acetaldehyde synthesis does not influence the maintenance of chronic ethanol
intake. However, a prolonged ethanol withdrawal partly returns the requirement for
acetaldehyde synthesis/levels both on chronic ethanol intake and on alcohol relapse-like
drinking. Chronic ethanol intake, involving the action of lipopolysaccharide diffusing
from the gut, and likely oxygen radical generated upon catechol/salsolinol oxidation,
leads to oxidative stress and neuro-inflammation, known to potentiate each other. Data
show that the administration of N-acetyl cysteine (NAC) a strong antioxidant inhibits
chronic ethanol maintenance by 60%–70%, without inhibiting its initial intake. Intra-
cerebroventricular administration of mesenchymal stem cells (MSCs), known to release
anti-inflammatory cytokines, to elevate superoxide dismutase levels and to reverse
ethanol-induced hippocampal injury and cognitive deficits, also inhibited chronic ethanol
maintenance; further, relapse-like ethanol drinking was inhibited up to 85% for 40 days
following intracerebral stem cell administration. Thus: (i) ethanol must be metabolized
intracerebrally into acetaldehyde, and further into salsolinol, which appear responsible
for promoting the acquisition of the early reinforcing effects of ethanol; (ii) acetaldehyde is
not responsible for the maintenance of chronic ethanol intake, while other mechanisms
are indicated; (iii) the systemic administration of NAC, a strong antioxidant markedly
inhibits the maintenance of chronic ethanol intake; and (iv) the intra-cerebroventricular
administration of anti-inflammatory and antioxidant MSCs inhibit both the maintenance
of chronic ethanol intake and relapse-like drinking.
Keywords: ethanol, acetaldehyde, catalase, relapse, reinforcement (psychology), inflammation, stem cells,
reactive oxygen species
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INTRODUCTION
This review addresses the biological factors that influence: (i) the
acquisition of alcohol intake; (ii) the maintenance of chronic
alcohol intake; and (iii) alcohol relapse-like drinking behavior in
animals bred for their high-ethanol intake.
Two animal lines derived from the Wistar strain generated
60 years ago (see Mardones and Segovia-Riquelme, 1983;
Quintanilla et al., 2006) have been kept for over 90 generations
by selective and genetic breeding. These are: an Abstainer
rat (UChA) line and a high-ethanol drinker line referred to
as Bibulous rat (UChB). The mechanisms leading to alcohol
rejection in the virtually abstainer UChA line are mainly
related to polymorphisms in nuclear and mitochondrial genes
that lead to a slow metabolism of acetaldehyde and to high
blood acetaldehyde levels. These UChA studies have been
previously described (Sapag et al., 2003; Quintanilla et al.,
2005, 2006; Israel et al., 2013) and thus not covered in the
present review. Studies conducted in UChB rats are indicated in
the text.
Alcohol-Use Disorders: Genetic Aspects
Since alcoholism is 40%–60% genetically determined (Heath
et al., 1997; Li, 2000), animals bred to consume high amounts
of alcohol while on a constant environment might provide an
answer for an elusive single ‘‘alcoholism gene’’ or the lack thereof.
It took years for science to conclude that there is no single
gene that could promote a high ethanol intake. Such a view
could already be derived from crosses between inbred mice with
markedly different ethanol intakes: the second generation (F2)
of crosses between high-intake (C57BL) and low intake animals
(DBA) results in animals presenting the complete alcohol intake
phenotype spectrum spanning their original strains (Phillips
et al., 1994).
While in human and animals, analyses of hundreds of genes
and genome-wide studies indicate that several polymorphisms
or chromosomal markers correlate with alcohol intake and/or
alcohol use disorders, these polymorphisms/markers have only
minor effects in predicting alcohol-use disorders, compared to
the marked effect of the polymorphisms of genes coding for
alcohol and acetaldehyde metabolizing enzymes. The reader is
referred to a recent review in this area (Tawa et al., 2016).
ACQUISITION OF ETHANOL INTAKE
The Reinforcing Effect of Ethanol-Derived
Brain Acetaldehyde
A number of studies in laboratories in Spain, Chile and
Italy, using Sprague-Dawley, UChB or Wistar rats, respectively
(Tampier and Mardones, 1979; Aragon and Amit, 1992; Peana
et al., 2008) have indicated that acetaldehyde generated in
the brain by the action of catalase mediates the ethanol
reinforcing mechanism. Acetaldehyde generated by the hepatic
metabolism of ethanol and present in blood at levels within
10–50 µM, does not cross the blood brain barrier (Eriksson
et al., 1977; Lindros and Hillbom, 1979; Petersen and Tabakoff,
1979; Stowell et al., 1980). However, large doses of exogenous
acetaldehyde are able to overcome the blood brain barrier
limitation. It has been shown that a single intraperitoneal
injection of 50 mg acetaldehyde/kg, resulting in blood levels of
350–400 µM acetaldehyde, doubles voluntary ethanol intake in
UChB rats (Quintanilla and Tampier, 2003). Thus, a large dose of
acetaldehyde sensitizes ethanol reinforcement in UChB rats. This
sensitizing effect may be mediated by brain-generated salsolinol
formed by the condensation of acetaldehyde and dopamine
(vide infra).
Operant self-administration studies have shown that rats bred
as alcohol high-drinkers (Indiana University, P and HAD rats)
will bar-press to self-administer both ethanol and acetaldehyde
into the ventral tegmental area (VTA). Noteworthy, the levels of
acetaldehyde required for self-administration into the VTA are
three orders of magnitude lower for acetaldehyde, in the range
of 10 µM than those for ethanol, which are in the range of
10–20 mM (Rodd et al., 2005). These studies indicate that as a
reinforcing agent acetaldehyde is more potent than ethanol.
Studies on the mechanisms that generate brain acetaldehyde
in Wistar rats show that catalase is responsible for 70% of the
brain oxidation of ethanol into acetaldehyde (Zimatkin et al.,
2006). Acetaldehyde is rapidly converted into acetate, likely via
a low Km aldehyde dehydrogenase (ALDH). In the presence of
ethanol, acetate levels in brain homogenates are 7-fold greater
than those of acetaldehyde (Zimatkin et al., 2006). Studies by
Zimatkin et al. (2006) also suggest that 15% of brain acetaldehyde
is generated from CYP2E1 (Figure 1).
Two types of studies conducted in UChB rats strongly suggest
that the generation of acetaldehyde in the VTA is an absolute
requirement for the acquisition of alcohol reinforcement:
(a) Genetic inhibition of catalase synthesis. Figure 2A shows
that the intra VTA administration of a lentiviral vector
coding for an anticatalase shRNA blocked ethanol intake
by 95%. It is noted that ethanol administration to Sprague-
Dawley and UChB rats significantly increases dopamine
release in nucleus accumbens (Imperato and Di Chiara,
1986; Di Chiara and Imperato, 1988; Quintanilla et al.,
2007; Bustamante et al., 2008), while blocking the synthesis
of catalase by the injection of the lentiviral vector coding
for an shRNA anticatalase abolished the increases in
FIGURE 1 | Ethanol metabolism into acetaldehyde and acetate in the
brain (Scheme from data of Zimatkin et al., 2006).
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FIGURE 2 | Anticatalase-Lentiviral vector (A) or aldehyde
dehydrogenase-2 (ALDH2)-coding Lentiviral vector (B) injection into the
ventral tegmental area (VTA) of naïve UChB rats markedly reduces voluntary
ethanol intake. A liver alcohol dehydrogenase (ADH)-coding Lenti vector
injection (C) significantly increases ethanol intake in ethanol naïve rats. Arrow
(Continued)
FIGURE 2 | Continued
indicates the time of administration of either control-lentiviral vector,
anticatalase- (A), ALDH2-lentiviral vector (B) or ADH-lentiviral vector
(n = 5 rats per group). UChB rats significantly (p < 0.001) reduced their
alcohol intake (10% v/v) when injected into the VTA with a lentiviral vector
coding for: (i) a shRNA against catalase (anticatalase-Lenti) (A); or
(ii) ALDH2-coding Lentiviral vector (B), compared to animals injected with an
empty lentiviral vector (control-Lenti). Rats significantly (p < 0.01) increased
their alcohol l (5% v/v) intake when injected with a lentiviral vector coding liver
ADH (C) (Panel A,C were adapted from Karahanian et al., 2011 and Panel B
was adapted from Karahanian et al., 2015).
dopamine release induced by ethanol administration. Such
an effect, studied in the UChB rat, was specific for
ethanol, since dopamine release induced by amphetamine
or KCl depolarization was not changed by the intra VTA
administration of the shRNA anticatalase coding lentiviral
vector (Karahanian et al., 2011)
(b) Transducing a gene encoding an enzyme that degrades
acetaldehyde. The administration to naïve UChB rats of a
lentiviral vector coding for the wildtype high affinity Aldh2,
aimed at increasing the VTA ability to degrade acetaldehyde
resulted in an 85% inhibition of ethanol (10% v/v) intake
(Karahanian et al., 2015; Figure 2B).
In addition to the above, transducing into the VTA a gene
coding for liver alcohol dehydrogenase (ADH), an enzyme that
generates acetaldehyde, increased 2–4 fold the reinforcing effect
of 5% ethanol (Karahanian et al., 2011; Figure 2C).
The above studies would preclude other brain systems in the
acquisition (development) of ethanol reinforcement in rats.
Systemic Acetaldehyde Can be Both
Aversive and Reinforcing
Systemic acetaldehyde generated endogenously at levels that do
not cross the endothelial cell layer of the blood brain barrier
is aversive (e.g the acetaldehyde protection against alcoholism
of East Asians carrying the ALDH2∗2 genotype). However high
systemic concentrations of acetaldehyde prior reached when
acetaldehyde itself is orally consumed or it is administered
intraperitoneally which can cross the blood brain barrier and
are reinforcing, as shown by Peana et al. (2010, 2011) in a
nose-poking for oral acetaldehyde in an operant model in Wistar
rats. Although blood acetaldehyde levels were not reported, these
studies further support the reinforcing-motivational role of brain
acetaldehyde and are in line with studies of Diana and associates
(Foddai et al., 2004) who postulated a preferential reinforcing
effect of systemic acetaldehyde over its aversive effects. In
UChB rats, Quintanilla and Tampier (2003) showed that the
injection of a large dose of acetaldehyde results in conditioned
place preference (CPP). Early studies by Brown et al. (1980)
demonstrated that infusion of acetaldehyde directly into the left
lateral ventricle of the brain of Wistar rats leads to increases in
ethanol intake. In this case the peripheral aversive effects are
expected to be minimal.
These findings, together with microdialysis studies (Melis
et al., 2007; Deehan et al., 2013a,b) show that local administration
of acetaldehyde into the posterior VTA leads to increases in
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dopamine release in nucleus accumbens further suggesting that
the reinforcing effect of acetaldehyde is mediated by activation
of dopaminergic neurons. Thus, the effect of acetaldehyde on
dopamine release mimics the effects of many drugs of abuse (Di
Chiara and Imperato, 1988).
Overall, literature studies support the view that brain
acetaldehyde is reinforcing. The possibility that acetaldehyde
may be converted into another reinforcing substance is
subsequently discussed.
The Reinforcing Effect of Salsolinol:
An Acetaldehyde-Derived Product
Ethanol-derived acetaldehyde condenses non-enzymatically with
brain dopamine to generate racemic (R/S)-salsolinol (R/S-
SAL; Figure 3). Rodd et al. (2008) and Deehan et al.
(2013b) have shown that (R/S)-SAL at concentrations of
0.03–0.3 µM is self-administered intra VTA by Wistar rats.
These concentrations of (R/S)-SAL are one to two orders
of magnitude lower than the concentrations required for
acetaldehyde self-administration in the same brain area.
Microinjections of (R/S)-SAL into the VTA of Wistar rats
also result in an increased release of dopamine in the nucleus
accumbens (Deehan et al., 2013a,b). Rommelspacher et al. (1995)
showed that SAL was increased in the blood of alcoholics.
Animal studies have shown that chronic ethanol administration
to Sprague-Dawley and to high alcohol drinker (HAD) rats
results in a significant increase of SAL levels in dopamine-rich
areas of the brain (Sjöquist et al., 1982; Matsubara et al., 1987;
Rojkovicova et al., 2008).
Several questions arise in relation to the action of SAL:
(i) is endogenous dopamine required to generate SAL? (ii)
does the chronic administration of (R/S)-SAL generate a
sensitized state similar to that generated by chronic ethanol
intake, which augments ethanol reinforcement? (iii) does (R/S)-
SAL administration to naïve rats induce ethanol motivational
effects? (iv) is there an enantiomer specificity distinguishing the
effects of R-salsolinol vs. S-salsolinol; and (v) does (R/S)-SAL
FIGURE 3 | Condensation of dopamine and acetaldehyde yielding
salsolinol. Schematic representation of the spontaneous condensation of
acetaldehyde with dopamine, yielding salsolinol (adapted from King et al.,
1974; Bates et al., 1986).
administration result in locomotor sensitization, as it happens
after chronic ethanol administration?
As will be discussed below; the answer to all these questions is
‘‘yes’’:
(i) In vitro studies by Melis et al. (2015) showed that inhibition
of dopamine synthesis by α-methyl-p-tyrosine, a tyrosine
hydroxylase inhibitor, fully abolishes the ability of ethanol
and acetaldehyde to activate VTA dopaminergic neurons, an
effect that was specific for ethanol and acetaldehyde (as SAL
precursors) but was not seen for pre-formed SAL.
(ii) Intra-cerebroventricular (Figure 4A) or systemic
administration of (R/S)-SAL (Figure 4B) to ethanol
FIGURE 4 | Prior salsolinol administration increases voluntary ethanol
intake in UChB rats. (A) UChB rats (n = 5) pretreated with salsolinol into the
VTA (30.0 pmol/0.2 µl; days 1, 3, 8, 12; arrows) increased ethanol intake
(60 min/day) during seven consecutive days (stippled bars), vs. rats pretreated
with artificial cerebrospinal fluid (aCSF; n = 5) into the VTA (0.2 µl; days 1, 3, 8,
12; arrows; white bars). (B) UChB rats (n = 5) pretreated with systemic
salsolinol (10 mg/kg, i.p.; days 1, 3, 8, 12; arrows) increased ethanol intake
(60 min/day) during seven consecutive days (striped bars), vs. UChB rats
(n = 5) pretreated with saline (7 ml/kg, i.p.; days 1, 3, 8, 12; arrows; white
bars) (Data from Quintanilla et al., 2014). Symbol ∗ means significant difference
from aCSF control rats p < 0.001 (Two way ANOVA).
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naïve UChB rats induces major increases in voluntary
ethanol intake (Quintanilla et al., 2014). This effect was
also observed by Myers and Melchior (1977) in Sprague-
Dawley rats. Noteworthy, the high ethanol intakes are of
the same order as those ingested by rats that had consumed
ethanol for several weeks and were exposed to the ethanol
deprivation condition followed by ethanol re-access (vide
infra).
(iii) Studies by Quintanilla et al. (2016a), in UChB rats showed
that the intra-cerebroventricular or systemic administration
of (R/S)-SAL increased the motivational effects of ethanol as
shown by the place preference technique (Figure 5), in line
with studies by Matsuzawa et al. (2000) in Sprague-Dawley
rats and by Hipólito et al. (2011) in Wistar rats.
FIGURE 5 | Salsolinol, injected intracerebrally or systemically,
produced conditioned place preference (CPP) in UChB rats. Salsolinol
or vehicle was administered either (A) intra-VTA (30 pmol/left VTA) or
(B) intraperitoneally (10 mg/kg, i.p.) in UChB rats (n = 28). Data are
means ± SEM and represent the time spent in the salsolinol-paired
compartment (seconds; means ± SEM, n = 7 for each group; ordinate) during
the pre- (white columns) and postconditioning (gray columns) phases. Asterisk
represents significant difference in time spent by the salsolinol group on the
salsolinol-paired side in the postconditioning phase vs. the preconditioning
phase and vs. the vehicle group: ∗p < 0.001 (two-way ANOVA) (Data from
Quintanilla et al., 2014).
(iv) Intracerebral administration studies in UChB rats showed
that the ethanol motivational and intake sensitization effects
of (R/S)-SAL is also seen with R-SAL while the S-SAL
enantiomer is inactive (Figure 6; Quintanilla et al., 2016a).
Although the pharmacological mechanisms responsible for
the action of (R/S)-SAL remain unclear, the specific effect
of the R-enantiomer in inducing the motivational effects
of ethanol, suggests that in vivo the chirality of the C-1
center of (R/S)-SAL plays an important role in changing its
affinity for transporters or receptors associated with ethanol
intake.
(v) The administration of (R/S)-SAL to Wistar or UChB rats
induced a sensitization to its locomotor effects (Hipólito
et al., 2010; Quintanilla et al., 2014).
In addition to the above, the findings that microinjections of
salsolinol into the posterior VTA increase dopamine release in
nucleus accumbens (Hipólito et al., 2011; Deehan et al., 2013a)
suggest that the reinforcing effect of salsolinol is mediated by the
activation of dopaminergic neurons.
Overall, the above studies suggest that brain SAL mediates the
effect of ethanol-derived acetaldehyde to motivate the acquisition
of ethanol consumption. Further, these studies are also in line
with the work of Rodd and associates (Rodd et al., 2008; Deehan
et al., 2013b) who showed that rats will self-administer (R/S)-SAL
into the posterior VTA at concentrations that are below those
required for acetaldehyde self-administration.
MAINTENANCE OF CHRONIC ETHANOL
INTAKE
Ethanol-Derived Acetaldehyde Is no
Longer Required to Maintain Chronic
Alcohol Intake
Studies by Quintanilla et al. (2012) and Karahanian et al. (2015)
have shown that after the UChB rats have reached a steady
state of chronic ethanol intake, the administration into the
VTA of either a lentiviral vector coding for an anti-catalase
shRNA (Figure 7A) or coding for the high affinity Aldh2 do
not influence voluntary ethanol intake (Figure 7B). It is noted
that the unabated ethanol intake seen in these studies after the
transduction of genes aimed at lowering acetaldehyde levels is
not due to negative reinforcement since addition of quinine
(bitter taste) to the ethanol solutions fully inhibits ethanol intake
(Quintanilla et al., 2012).
The failure of the anticatalase or ALDH2 coding lentiviral
vectors to reduce ethanol intake in rats that had consumed
alcohol for 2 months suggests that following chronic alcohol
consumption other signaling pathways might be recruited.
Chronic consumption of drugs of abuse induces changes at the
molecular, cellular and neurocircuitry levels that mediate the
transition from occasional, controlled substance use to loss of
control in drug intake and chronic addiction (Koob and Le Moal,
2008). Although chronic drug consumption induces changes in
several neurotransmitter systems, including dopamine, GABA,
cannabinoids and opioid systems (see Fattore and Diana, 2016),
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FIGURE 6 | Prior repeated administration of (R)-SAL, but not of (S)-SAL, increases voluntary ethanol intake in ethanol-naïve UChB rats. UChB rats
(n = 5 rats per group) were pretreated intra-VTA with (R)-SAL (black columns), (S)-SAL (gray columns) or control aCSF (white columns) on days 1, 3, 5 and 13
(arrows); then (from day 14) animals were exposed to ethanol for 1 h/day. Asterisk symbol (∗P < 0.05) indicates that the ethanol intake is significantly higher than that
of the control (aCSF) group of the same day. Single plus (+ cross-like) sign indicates that the ethanol intake of (S)-SAL treated animals is significantly different lower
(p < 0.001) than that of the (R)-SAL group on the same day (Data from Quintanilla et al., 2016a).
without implying a lesser role for other neurotransmitter
systems, we mainly focus our review on glutamate transmission
since: (i) many addictive drugs lead to an increased glutamatergic
signaling (Wolf et al., 2003; Koob and Volkow, 2010); which
(ii) drive the enhanced motivation to obtain several drugs,
including cocaine (Kalivas and McFarland, 2003; Pickens et al.,
2011) and, now also ethanol (Sari et al., 2013; Das et al., 2015);
and (iii) can be modified by the administration of drugs that
normalize the glutamate homeostasis (vide infra).
The Hyperglutamatergic Hypothesis
Mechanisms that lead subjects to maintain drug intake involve:
(a) learned cues (see Volkow et al., 2002; Hyman et al.,
2006; Berridge et al., 2009); for ethanol likely its odor (see
Bragulat et al., 2008); and (b) an increased glutamatergic tone
(see Reissner and Kalivas, 2010). An increased glutamatergic
tone has been shown in Sprague-Dawley rats to be associated
with the maintenance of chronic ethanol intake, as well as
with the relapse of several drugs of abuse (Weiland et al.,
2015). Alcohol preferring rats (P strain) on a chronic ethanol
intake schedule show marked increases in extracellular glutamate
in nucleus accumbens (Ding et al., 2012), resulting from
a reduction in the levels of the Na+-glutamate (exchange)
transporter (GLT1) in astrocytes of tripartite glutamatergic
synapses. Sari et al. (2013) studied the maintenance of chronic
ethanol intake in P rats. In these studies, the administration of
ceftriaxone, a drug that increases the levels of GLT1, resulted
in a 60%–70% reduction in chronic ethanol intake. Das et al.
(2015) confirmed an elevation of extracellular glutamate in
nucleus accumbens of P rats exposed to ethanol chronically,
and showed that ceftriaxone markedly inhibited chronic ethanol
intake.
Studies in Sprague-Dawley rats show that extracellular
glutamate levels are regulated not only by the astrocyte Na+
gradient-dependent GLT1 transporter but also by the astrocyte
exchange of cystine for glutamate via the cystine/glutamate
exchanger (Herrera-Marschitz et al., 1996; Baker et al., 2003).
Scofield and Kalivas (2014) demonstrated that a number of drugs
of abuse reduce the levels of the GLT1 transporter and increase
the extracellular levels of glutamate. In rodents, operant cocaine
self-administration reduces both the nucleus accumbens cystine-
glutamate exchange and glutamate transport by the GLT-1
transporter. Most importantly, administration of the antioxidant
drug N-acetyl cysteine (NAC) normalizes these two processes.
Reissner et al. (2015) concluded that restoring GLT-1, not the
cystine-glutamate exchange, is the key mechanism whereby daily
NAC reduces the hyperglutamatergic state.
The Administration of N-Acetyl Cysteine
in Drug Dependence and Motivation
A number of studies have shown that NAC reduces relapse (or
reduces CPP) of many addictive drugs including: (i) cocaine
(Madayag et al., 2007; Moussawi et al., 2009; Reichel et al.,
2011; Kupchik et al., 2012; Reissner et al., 2015); (ii) nicotine
(Ramirez-Niño et al., 2013; Bowers et al., 2016; Moro et al.,
2016); (iii) heroin (Zhou and Kalivas, 2008); and now (iv) ethanol
(Quintanilla et al., 2016b).
Most of the above studies were conducted in rodents, while
only one clinical study has reported the effect of NAC on a
drug use disorder (LaRowe et al., 2013). These investigators
indicated that their studies failed to demonstrate that NAC
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FIGURE 7 | Injection of an shRNA anti-catalase (A) or ALDH2 coding
vector (B) into the VTA did not reduce alcohol (10%) intake in UChB rats that
had chronically ingested ethanol. Arrow indicates the time of administration in
(A) control-lentiviral vector (--) or anticatalase-lentiviral vector (-N-) and in
(B) the control-lentiviral vector (--) or the ALDH2-coding vector (-4-). The
number of animals was 8 or 10 rats/group. Neither the anticatalase, the
ALDH2-coding vector nor the control vector modified the voluntary ethanol
intake of the animals that had already been under free choice ethanol
consumption for 60 days (Panel A was adapted from Quintanilla et al., 2012
and Panel B was adapted from Karahanian et al., 2015).
reduced cocaine use in cocaine-dependent individual actively
self-administering the drug. However, they also report that NAC
prevented the return to cocaine use (relapse) in individuals who
had already achieved abstinence from cocaine. In the latter,
NAC administration reduced cocaine relapse by 90% (LaRowe
et al., 2013; Figure 2). Despite the promising studies showing
an inhibition of cocaine relapse in animals, these studies in
abstinent cocaine users will require confirmation before their
clinical application.
A possible explanation for the effect of NAC in preventing
cocaine relapse only in detoxified patients may relate to the dual
effect of cocaine in generating oxygen radicals (ROS) in the
brain: (i) cocaine inhibits both the dopamine transporter and the
norepinephrine transporter (Dohi et al., 2002), thus increasing
the exposure of both extracellular dopamine and norepinephrine
to a physiological pH, which leads to the autooxidation
of catecholamines, generating one-electron oxidant semi-
quinones; and (ii) both neurotransmitters are deaminated by
monoamine oxidases generating hydrogen peroxide (Kopin,
1994). Thus, NAC is expected to be considerably less active
when cocaine continues to be self-administered, while most
active in a condition where only the remaining cocaine-
induced ROS self-potentiating effects promote drug relapse.
Amphetamine-like drugs have similar properties as cocaine in
generation of ROS as amphetamines release not only dopamine
but also norepinephrine (Rothman et al., 2001). McClure et al.
(2014) suggest that NAC may prove to be an ideal relapse
prevention aid when given after periods of abstinence or
when combined with other forms of pharmacological and/or
behavioral treatments to promote abstinence.
Despite the above, NAC markedly inhibited the chronic
intake of ethanol of rats (vide infra). Animals were
chronically self-administering alcohol; thus not in an abstinent
condition (Quintanilla et al., 2016b), suggesting that the
ROS/neuroinflammation generated by chronic ethanol intake
is less intense than that generated by drugs that increase the
extracellular levels of both dopamine and norepinephrine. We
are not aware of clinical studies aimed at testing the effect
of NAC as a treatment of alcoholism, whether prior or after
abstinence. However, a recent clinical study showed that when
successful, NAC treatment of marihuana users also reduced their
alcohol use (Squeglia et al., 2016).
As shown by Quintanilla et al. (2016b) the daily
administration of NAC, although not inhibiting the acquisition
of chronic ethanol intake (Figure 8A), was a strong inhibitor
(70%–75% reduction) of ethanol intake maintenance
(Figure 8B). These results are in line with the findings of
Doyle et al. (2014) indicating that glutamatergic signaling in
the nucleus accumbens of Sprague-Dawley rats, although not
essential for modifying initial cocaine use in non-addicted stages,
becomes critical for post withdrawal relapse after the addiction
has developed.
Oxidative Stress and Neuroinflammation:
A General Role in the Addiction Process
Several studies indicate that oxidative stress is a relevant
mechanism contributing to neural cytotoxicity and behavioral
changes associated with drug addiction (see Cunha-Oliveira
et al., 2013). Oxidative stress in the nervous system has been
found upon in vivo exposure to amphetamine or amphetamine
derivatives (Frey et al., 2006; Jung et al., 2010) and heroin
(Qiusheng et al., 2005; Xu et al., 2006). Withdrawal from cocaine
or heroin also induces oxidative stress in rodent’s brain (Cemek
et al., 2011; Pomierny-Chamiolo et al., 2013). The effect NAC
in both normalizing glutamate levels and reducing drug relapse
(Reissner et al., 2015) likely results from its high antioxidant
activity. N-acetylcysteine is also used to treat an acetaminophen
overdose due to its high antioxidant activity, being a precursor of
cysteine and glutathione (Lucyk et al., 2016).
A number of studies in Wistar and Sprague-Dawley rats
have shown that chronic ethanol administration leads to both
oxidative stress and neuroinflammation (reviewed by Crews
et al., 2015; Crews and Vetreno, 2016). Noteworthy, oxidative
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FIGURE 8 | Chronic N-acetyl cysteine (NAC) administration (30 or
60 mg/kg, i.p.) administered during the acquisition of alcohol
consumption did not reduce ethanol intake (A), but given during the
chronic ethanol maintenance phase markedly reduced ethanol intake (B) in
UChB rats. Three groups of rats (n = 5 rats per group) under continuous
access to 10% ethanol and water were treated with either saline (black
square), 30 mg/kg NAC i.p. (black triangles), or 60 mg/kg N AC i.p (black
circles) from day 5–18 (acquisition phase) of ethanol intake (A). Different
groups of rats under continuous access to 10% ethanol and water rats
(n = 5 rats per group) were treated with either saline (black square), 30 mg/kg
NAC (black triangles), or 60 mg/kg NAC (black circles) from day 65 to day 78
(maintenance phase) of ethanol intake (B). Data are means ± SEM of daily
ethanol intake. Asterisk symbol ∗p < 0.05, indicates that the ethanol intake is
significantly lower than that of the saline control group of the same day. (§)
Symbol p < 0.001, indicates that the ethanol intake of NAC 60 mg/kg group
is lower than that of NAC 30 mg/kg group (Data from Quintanilla et al., 2016b).
stress and neuroinflammation potentiate each other via the
oxidation of IκB with activation of NFκB and the generation
of inflammatory cytokines; the latter in turn generate oxygen
radicals via mitochondrial uncoupling (Kastl et al., 2014).
Montesinos et al. (2016) reviewed the direct relationship between
neuroinflammation and brain injury. In alcoholics, a marked
hippocampal cell loss and injury has been shown (Sullivan
et al., 1995). Long Evans rats that consume alcohol for several
months in nutritionally adequate liquid diets also display
marked hippocampal damage (Walker et al., 1980). Studies in
C57/BL mice have shown that chronic alcohol intake increases
brain TLR4 and NF-κB, both involved in the generation of
inflammatory cytokines (Alfonso-Loeches et al., 2010).
In a most relevant study causally linking neuroinflammation
to an increased ethanol intake, Blednov et al. (2011) showed
long-lasting increases in ethanol intake in C57/BL mice
following the administration of a single dose of bacterial
lipopolysaccharide, a well know neuroinflammatory agent,
thus increasing the reinforcing effect of ethanol. Ethanol
intake, via gut-generated acetaldehyde, induces the entrance
of intestinal lipopolysaccharide into the blood (Ferrier et al.,
2006), which via TNF-α generates neuroinflammation (see
Crews et al., 2015). Additionally, in the brain itself a
pro-oxidant and pro-inflammatory agent generated from ethanol
is salsolinol; an oxygen radical-generating agent when oxidized
into semi-quinones by metals ions present in biological
systems (Jung and Surh, 2001). Thus, oxygen radicals and
lipopolysaccharide potentiate each other in generating a
neuroinflammation.
An additional link between neuroinflammation and an
increased glutamatergic signal has been recently reported
(David et al., 2016). The authors demonstrated a significant
reduction in the primary astrocytic glutamate transporter, GLT-1
and increases in extracellular glutamate levels induced by
neuroinflammation following an infection due to toxoplasma
administration to mice. Thus, these studies further support the
sequence oxidative stress/neuroinflammation—low glutamate
transporter—hyperglutamatergic state.
Overall, the studies reviewed indicate that different
mechanisms are responsible for the acquisition of ethanol intake
and for its chronic maintenance. A number of studies strongly
support the view that chronic ethanol intake is maintained
by mechanisms known to increase the extracellular levels of
brain glutamate, likely in nucleus accumbens. The inhibition of
chronic ethanol intake by NAC, a strong antioxidant, further
suggests that the reactive oxygen species/neuroinflammation
system plays a role in chronic ethanol maintenance. The
reactive oxygen radical species and inflammatory cytokines (e.g.,
TNF-alpha) are known to potentiate each other.
RELAPSE-LIKE ALCOHOL INTAKE
Following Ethanol Deprivation, Ethanol
Intake Upon Re-Access Is Again
Dependent on Brain Acetaldehyde
In UChB rats ingesting ethanol chronically for 2-months, a
4-week ethanol deprivation leads to a partial recovery of the
inhibitory effect of the anti-catalase vector on ethanol intake
(Figure 9; Quintanilla et al., 2012). The fact that the effect on 24-h
ethanol intake is not seen immediately after ethanol re-access
may relate to the marked intake in the first few hours following
the alcohol deprivation and re-access, in line with studies of
Hölter and Spanagel (1999); Rodd et al. (2009) and Vengeliene
et al. (2014) for Wistar and HAD rats.
The relapse-like drinking also known as the ‘‘alcohol
deprivation effect’’ (ADE) is a condition in which animals
subjected to chronic ethanol intake followed by a long
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FIGURE 9 | A period of alcohol deprivation is required to reduce
voluntary alcohol intake following the anticatalase-lentiviral vector
administration into the VTA in UChB rats. UChB rats (n = 10 rats per
group) allowed to access 10% ethanol and water on a 24-h basis for
2 months did not change their voluntary alcohol intake when these were
subsequently injected into the VTA with a single dose of a lentiviral vector
coding for an shRNA against catalase (anticatalase-Lenti), but significantly
(ANOVA; F(1,33) = 111.54, p < 0.001) reduced (50%) their alcohol intake
following 4 weeks of alcohol deprivation when compared to the ethanol intake
of animals (n = 10) that received a control lentiviral vector (control-Lenti). After
the alcohol deprivation period, the animals were returned to a free access of
10% ethanol and water on a 24-h basis (Data from Quintanilla et al., 2012).
deprivation, consume intoxicating amounts of ethanol in as little
as 60-min upon ethanol re-access. The ADE paradigm in animals
has good predictive value in representing relapse-like drinking
in humans as it is inhibited by three medications used clinically
to reduce ethanol intake, namely: naltrexone, nalmefene and
acamprosate-Ca (Spanagel and Zieglgänsberger, 1997; Orrico
et al., 2014; Spanagel et al., 2014), indicating that several
neurotransmitter systems- including a hyperglutamatergic tone
and importantly the opiate system also mediate ADE. As will
be discussed below, acetaldehyde also plays a role in relapse-like
ADE drinking.
In the ADE model in UChB rats, chronic ethanol intake for
1–3 months is interrupted by an alcohol deprivation of 7–15 days
before animals are allowed ethanol re-access. Upon ethanol
re-access, animals consume intoxicating amounts of ethanol of
the order of 2–2.5 g ethanol/kg/in the first 60 min of re-access
(Tampier et al., 2013; Karahanian et al., 2015). In the UChB
model, ethanol intake studies in the ADE condition were aimed
at dissociating ADE ethanol intake from the ethanol ‘‘drinking-
in-the-dark’’ condition, where high ethanol intakes are observed
primarily if water is not offered (Thiele et al., 2014). Since,
as shown in Wistar and P rats, the endogenous opiate tone
is increased upon food intake (Jalowiec et al., 1981) which is
per se involved in ethanol intake (Froehlich et al., 1990), the
studies in UChB rats were conducted at 1–2 PM (on a 7 AM to
7 PM normal light cycle). Animals rapidly and almost exclusively
approach the alcohol solution bottles and not the water bottles,
consuming minimal amounts of water upon re-access. A large
ADE-induced intake is observed mainly during the initial hour of
ethanol re-access (Tampier et al., 2013; Karahanian et al., 2015),
in line with studies of Hölter and Spanagel (1999) and Rodd
et al. (2009) for HAD and Wistar rats, respectively. The latter
authors have demonstrated that on ethanol re-access in the ADE
condition, animals are willing to work for alcohol to a greater
extent (e.g., to a higher bar-pressing breakpoint), suggesting a
more rewarding effect of ethanol in such condition (Hölter et al.,
1998). An additional characteristic of the ADE mechanism is
‘‘kindling-like’’ effect that increases the post ADE ethanol intake
following several periods of ethanol deprivation and ethanol
reinstatement (Hölter and Spanagel, 1999; Rodd et al., 2009), a
characteristic also observed in UChB rats (Tampier et al., 2013;
Karahanian et al., 2015; Figures 10A,B). Figures 10A,B further
show that the deprivation period partly allows the recovery of
the inhibitory effect on ethanol intake exerted by the intra-VTA
administration of a lentiviral vector coding for an anticatalase
shRNA or an ALDH enzyme (Tampier et al., 2013; Karahanian
et al., 2015). These findings are in line with the observations of
Muggironi et al. (2013) and Orrico et al. (2013) who showed
that administration of penicillamine, an acetaldehyde trapping
agent, partly inhibited the relapse-like alcohol intake in Wistar
rats. Vengeliene et al. (2005) showed in Wistar rats that the i.p.
administration of ethanol prior to oral re-access (which per se
generates acetaldehyde before oral ethanol intake occurs) partly
reduced ADE ethanol intake upon re-access.
Overall, studies show that in animals that have consumed
ethanol chronically and are subjected to a protracted abstinence
followed by ethanol re-access, brain-derived acetaldehyde plays a
significant role in the relapse-like drinking. Noteworthy, relapse
drinking is a characteristic of alcoholism in humans.
Maintenance and Relapse-Like Alcohol
Drinking: Stem Cells Administration
As indicated above, neuroinflammation leads to cognitive
dysfunction and increases chronic alcohol intake (Blednov
et al., 2011; Crews and Vetreno, 2016; Montesinos et al.,
2016). These studies suggest that reducing neuro-inflammation
could reduce both chronic ethanol intake (maintenance) and
possibly relapse-like drinking. Developments in the stem cell
field have shown that most tissues contain mesenchymal stem
cells (MSCs; Prockop et al., 2010), known to be activated by
inflammatory mediators (e.g., TNFα) in damaged areas, leading
to the generation of anti-inflammatory cytokines including IL-10
(Lee et al., 2016) and a soluble TNFα receptor, which neutralizes
TNFα (Yagi et al., 2010). MSCs can be isolated and expanded
from a number of tissues, such as bone marrow and adipose
tissue (Contador et al., 2015; Ezquer et al., 2016).
Yang et al. (2015) showed that hippocampal apoptosis
and neurocognitive impairments generated by chronic ethanol
administration in Sprague-Dawley rats could be reversed by the
infusion of mesenchymal bone marrow stem cells. The study
indicated that increases in hippocampal superoxide dismutase
(which lowers oxidative stress and likely neuroinflammation) as
well as increases in neural growth factor were associated with the
reversal of apoptosis and cognitive deficits.
Recent work in UChB rats (Israel et al., 2017) tested whether
MSCs from bone marrow or adipose tissue of ethanol-naïve rats
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FIGURE 10 | A single VTA area injection of a shRNA
anticatalase-coding lentiviral vector (A) or an ALDH2-coding lentiviral
vector (B) inhibit first-hour ethanol (EtOH) relapse-like ethanol intake after the
first and second and third deprivation periods. Baseline data correspond to
the average of EtOH intake restricted to only 1 h a day, for 7 days immediately
prior to alcohol deprivation before intra-VTA injections (A,B) by UChB rats.
Control-Lenti or Anticatalase-Lentiviral vector (n = 5 rats per group) were
injected during the first day of deprivation (A). Control-Lenti or
ALDH2-lentiviral vector (n = 5 rats per group) were injected during the first day
of deprivation (B). The -/ /- symbol in the x-axis represents the 15-day
deprivation period. The first, second and third re-exposure consumptions
were ∗symbol, means significant different from control-Lenti p < 0.001; and
†symbol, means significant different from its own baseline value p < 0.01
(Panel A was adapted from Tampier et al., 2013 and Panel B, was adapted
from Karahanian et al., 2015).
injected intra-cerebroventricularly could inhibit chronic ethanol
intake both in the maintenance condition and in the relapse-
like condition induced by the ethanol deprivation effect (ADE).
Figure 11 shows the inhibitory effect of MSCs on intake of
ethanol of rats that had freely ingested 10% ethanol for 3 months.
Data show that a significant inhibition of ethanol intake exerted
by the MSCs; a single dose of MSCs (5× 105 cells in 5 µL)
FIGURE 11 | Intra cerebroventricular injection of bone marrow-derived
mesenchymal stem cell (MSC) or adipose tissue—MSC reduces
chronic 24-h ethanol consumption in UChB rats. Rats under chronic
ethanol access were injected with bone marrow-derived or adipose
tissue—derived MSCs or vehicle into the left cerebral ventricle (n = 5 rats per
group). Ethanol consumption is shown as g ethanol/kg/day. Asterisk
∗p < 0.001 indicates a reduction of ethanol intake compared to vehicle during
all MSCs post-treatment days (Data from Israel et al., 2017).
injected into the brain lateral ventricle reduced by 40%–60% the
maintenance of chronic alcohol intake for the 10 days studied.
Relapse-like alcohol intake as affected by MSCs under the
ADE condition, was studied in a separate group of UChB
rats. Animals that had freely consumed ethanol solutions
for 87 days were deprived of ethanol for 14 days. On the
fourth day of deprivation animals were administered the MSCs
and on deprivation day 15 animals had re-access to ethanol
solutions. Prior to the alcohol deprivation, animals displayed
a basal alcohol intake of 1.1 g ethanol/kg/60 min (Figure 12),
intake which was doubled after repeated alcohol deprivation
(ADE) and re-access cycles, reaching 2.2 g alcohol/kg/60 min
(equivalent to the consumption of over 10 standard drinks/70 kg
in a 1-h sitting). Data in Figure 12 show that animals
treated with MSCs reduced up to 80%–85% their relapse-like
alcohol intake compared to sham control rats. There were no
significant differences between the effects of bone marrow-
derived MSCs and adipose tissue-derived MSCs. It is noted
that a single intra-cerebroventricular injection of both MSC
types inhibited relapse-like drinking for the 40 days investigated,
suggesting a marked inhibition of the ADE-activated brain
reward systems.
Overall, the inhibition of ethanol intake by MSCs, both
under chronic and relapse-like conditions, further supports
the view that chronic ethanol intake is maintained by brain
oxidative stress/neuroinflammatory conditions, also indicating
a role of inflammatory mechanisms on relapse-like ethanol
intake. Noteworthy is the long-lasting inhibition afforded by a
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FIGURE 12 | Intra cerebroventricular injection of bone marrow-derived
or adipose-tissue derived MSCs block relapse-like (60-min) ethanol
intake in UChB rats. Rats allowed 87 days of free-choice ethanol access
were injected on the fourth day of deprivation with bone marrow-derived MSC
(gray columns), adipose tissue-derived MSC (black columns) or vehicle
(dashed columns) in the left cerebral ventricle (n = 5 rats per group) and
deprived of ethanol for 14-days, after which ethanol re-access was allowed.
Animals were further subjected to three additional cycles of 3 days of
ad libitum ethanol drinking and further 7-days of deprivation prior to the next
ethanol re-access. The symbol / / represents the deprivation period prior to
ethanol re-access: (a) 14-day deprivation, (b) 7-day deprivation.
∗p < 0.001 and ++p < 0.05 indicate ethanol intake increases vs. baseline.
§p < 0.001 indicates a reduction of ethanol intake compared to baseline value
for each of the MSC types (Data from Israel et al., 2017).
single administration of MSCs on the relapse-like ethanol intake
condition.
CONCLUSIONS
The studies presented:
(a) Confirm, by the use of genetic modifications, studies by
several groups in several rat strains that had indicated
that catalase-mediated brain oxidation of ethanol
into acetaldehyde is required for animals to initiate
(acquisition) chronic ethanol intake. In the UChB rat,
brain-derived acetaldehyde was shown to be an absolute
requirement (80%–95%) for the initiation of chronic ethanol
intake.
(b) Demonstrate that after a steady chronic ethanol intake
(maintenance) has been attained, brain acetaldehyde
generation is no longer required to perpetuate its intake.
This effect seen in UChB and Wistar rats has also been
observed in operant ethanol self-administration studies
in mice. Following a protracted ethanol deprivation,
acetaldehyde is again required to induce a relapse-like
condition.
(c) Demonstrate that the daily administration of the antioxidant
drug N-acetyl cysteine to UChB rats that have consumed
ethanol chronically markedly inhibits (70%–75%) voluntary
ethanol intake. Noteworthy, N-acetyl cysteine did not inhibit
the initial acquisition of ethanol intake of naïve animals.
(d) Demonstrate in UChB rats that the intracerebral
administration of salsolinol—the condensation product
of dopamine and acetaldehyde—results in enhanced ethanol
reinforcement, leading to binge-like ethanol intakes (up to
3 g ethanol/kg in 60 min, equivalent to 15 drinks/70 kg) and
in an enhancement of ethanol motivational effects as shown
by the place preference technique.
(e) Demonstrate that a single intra-cerebroventricular
administration to UChB rats of mesenchymal stem cells,
known to have marked anti-inflammatory and antioxidant
properties, inhibited relapse-like ethanol drinking by
60%–85% for 40 days.
(f) Overall, studies indicate that ethanol-derived metabolites
are by themselves involved in the acquisition of ethanol
intake; while these metabolites are indirectly involved
in maintenance of chronic ethanol intake and in
relapse-like ethanol drinking. A new element playing
a role in maintenance and relapse-like drinking is
neuroinflammation, partly mediated by acetaldehyde
increasing the diffusion of gut lipopolysaccharide into
the systemic circulation and possibly by oxygen radicals
generated in the oxidation of salsolinol.
A final note, while many of the studies discussed have been
conducted in rodents of different species and strains or in cells,
extrapolation of these findings to humans requires caution.
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